FDA Updates Advice on Evaluating Common Symptoms in Outpatient COVID-19 Trials

The FDA has issued a new final guidance on assessing COVID-19-related symptoms in drug and biologics trials for outpatient prevention/treatment of the infectious disease, overriding its prior recommendations from September 2020.
Source: Drug Industry Daily